Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Robust population pharmacokinetic experiment design.

Michael G Dodds1, Andrew C Hooker, Paolo Vicini

  • 1Resource Facility for Population Kinetics, Department of Bioengineering, University of Washington, Box 352255, Seattle 98195-2255, WA, USA.

Journal of Pharmacokinetics and Pharmacodynamics
|October 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.

CPT: pharmacometrics & systems pharmacology·2026
Same author

A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score.

BMC medical research methodology·2025
Same author

Integrated Modeling of Digital-Motor and Clinician-Reported Outcomes Using Item Response Theory: Towards Powerful Trials for Rare Neurological Diseases.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Erratum to "INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(1): 100005.].

The journal of prevention of Alzheimer's disease·2025
Same journal

Cohort population analysis of sparse data: Dexamethasone pharmacokinetics in mother and fetus based on blood sampling at birth.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Bridging the operational gap in population pharmacokinetic-pharmacodynamic analysis: an international perspective on the 2025 Chinese group standard.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications.

Journal of pharmacokinetics and pharmacodynamics·2026
Same journal

Comparing heavy-tailed residual error models for outlier handling in population PK modeling.

Journal of pharmacokinetics and pharmacodynamics·2026
See all related articles

Designing optimal experiments for pharmacokinetic studies is crucial. ED-optimality offers a robust approach for parameter estimation, outperforming D-optimality when prior information is uncertain.

Area of Science:

  • Pharmacokinetics
  • Population modeling
  • Experimental design

Background:

  • Population pharmacokinetic (PK) studies utilize mixed-effects models to estimate drug properties.
  • Individual data in these studies is often sparse, necessitating efficient experimental design.
  • Traditional D-optimality requires precise prior parameter knowledge, which can be unavailable or misspecified, leading to suboptimal designs.

Purpose of the Study:

  • To address the limitations of D-optimality in population PK studies.
  • To introduce and evaluate the ED-optimality criterion for robust experimental design.
  • To demonstrate the effectiveness of ED-optimal designs when prior parameter information is uncertain.

Main Methods:

  • Developed a novel approximation for the expectation integral in ED-optimality, simplifying numerical solutions.

Related Experiment Videos

  • Employed stochastic integration techniques for solving the complex integral.
  • Validated the approach through two case studies using simulated population PK data.

    • Main Results:

    • ED-optimal designs demonstrate robustness against misspecified prior information.
    • Misspecified ED-optimal designs yield superior parameter estimates compared to similarly misspecified D-optimal designs.
    • Performance of misspecified ED-optimal designs approaches that of correctly specified D-optimal designs.

    Conclusions:

    • ED-optimality provides a more robust criterion for designing population PK experiments, especially with uncertain prior knowledge.
    • The novel approximation method makes ED-optimality numerically tractable.
    • ED-optimal designs enhance the reliability of parameter estimation in population PK studies.